Enliven Therapeutics, Inc. (NASDAQ: ELVN) reported Q1 EPS of ($0.80), $0.23 worse than the analyst estimate of ($0.57).

For earnings history and earnings-related data on Enliven Therapeutics, Inc. (ELVN) click here.